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c o n c i s e c o m m u n i c a t i o n
Severity of Clostridium difficile–
Associated Disease (CDAD)
in Allogeneic Stem Cell Transplant
Recipients: Evaluation of a CDAD
Severity Grading System
Erik R. Dubberke, MD; Justin Sadhu, BS;
Robert Gatti, BS; Kimberly A. Reske, MPH;
John F. DiPersio, MD, PhD; Steven M. Devine, MD;
Victoria J. Fraser, MD
The purpose of this study was to develop and test a Clostridium
difficile–associated disease (CDAD) grading system based on pre-
senting symptoms in allogeneic stem cell transplant recipients. Pa-
tients with severe CDAD had significantly shorter median survival
times and more adverse outcomes than patients with mild or mod-
erate CDAD.
Infect Control Hosp Epidemiol 2007; 28:208-211
Clostridium difficile–associated disease (CDAD) is the most
common infectious cause of healthcare-associated diarrhea.1
Allogeneic stem cell transplant recipients may be at increased
risk for severe CDAD because of their immunocompromised
state. However, studies of CDAD in hematopoietic cell trans-
plantation patients disagree about the incidence of, severity
of, and risk factors for CDAD.2-10 A lack of differentiation
between mild cases and severe cases of CDAD may explain
some of these discrepancies. To address this deficiency and
to further study CDAD outcomes among allogeneic stem cell
transplant recipients, we developed and validated a grading
system for CDAD severity using a modified version of the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0 (CTCAE) and based on the pre-
senting clinical CDAD symptoms.
methods
The study was conducted at Barnes-Jewish Hospital, a 1,250-
bed, tertiary care hospital in St. Louis, Missouri. A retro-
spective cohort study was performed that included all allo-
geneic stem cell transplant recipients who developed their
first episode of CDAD between August 1, 2001, and July 31,
2003. Cases were identified prospectively by the infection con-
trol department. Patients were excluded if they had a history
of CDAD before the study period. A case of CDAD was
defined by a stool toxin assay positive for C. difficile toxin
(Tech Lab). The decision to order a C. difficile toxin assay
was made by the patient’s treating physician on the basis of
the patient’s symptoms and risk factors. In addition, the mi-
crobiology laboratory tests stool samples for C. difficile only
if the stool sample conforms to the container in which it is
sent (ie, is unformed).
Patients’ medical records were reviewed to collect infor-
mation on demographic characteristics, underlying disease
status, symptoms, infections, complications, medications re-
ceived, and outcomes. Infections were defined using the Cen-
ters for Disease Control and Prevention National Nosocomial
Infections Surveillance System definitions.11,12 Patients were
followed up for 180 days after the date of CDAD diagnosis
to identify infections and determine mortality. Diarrhea was
defined as 3 or more loose bowel movements per day, for at
least 48 hours. Response to CDAD therapy was defined as
either a decrease in diarrhea by half or resolution of ileus
and resolution of any other associated symptoms.
The CDAD severity grading system was developed by mod-
ifying the criteria for grading diarrhea and colitis in the
CTCAE. The CTCAE is a standardized method of reporting
adverse events in cancer patients.13 Hypothermia (tempera-
ture of 35.6C or less, or 35.9C or less for more than an
hour) was added as a criterion for grade 3 colitis. The nursing
notes for the transplantation ward include an intake and out-
put assessment. Because intestinal output is recorded only if
diarrhea is present, total daily intestinal output was included
in the determination of diarrhea severity: 500 mL or less of
intestinal output per day was included in the definition of
grade 1 diarrhea; 501 to 1,000 mL in the definition of grade
2; 1,001 to 2,000 mL in grade 3; and more than 2,000 mL
in grade 4. Mild CDAD was defined as grade 1 diarrhea and/
or colitis. Moderate CDAD was defined as grade 2 diarrhea
and/or colitis. Severe CDAD was defined as grade 3 or higher
diarrhea and/or colitis. All symptoms had to be present within
48 hours of the time CDAD was diagnosed to be included
in the grading scale. For statistical analyses, mild and mod-
erate cases were grouped together and compared with the
severe cases.
Statistical analyses were performed with SPSS statistical
software, version 12.0 for Windows (SPSS). Statistical tests
used included the x2, Fisher exact, Mann-Whitney U, and
Kaplan-Meier tests. P values less than or equal to .05 were
considered statistically significant. The Washington University
Human Studies Committee approved this study.
results
Thirty-seven allogeneic stem cell transplant recipients met the
inclusion criteria. Sixteen patients (43%) were classified as
having mild or moderate CDAD and 21 (57%) as having
severe CDAD. No significant differences at baseline were
noted between patients who developed mild or moderate
CDAD and patients who developed severe CDAD with respect
to demographic characteristics, underlying disease, reason for
admission, transplant donor source (sibling vs unrelated),
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table. Outcomes for Patients With Clostridium difficile–Associated Disease (CDAD)
Outcome
Patients with mild
or moderate CDAD
(N p 16)
Patients with
severe CDAD
(N p 21) P
Therapy
Responded to therapy 15 (94) 19 (91) 1.0
Responded to therapy after 12 days 5 (31) 14 (67) .05
Treated with Mtz only 11 (69) 8 (38) .06
Treated with Mtz plus Vm or Vm only 4 (25) 12 (57) .05
Duration of treatment, mean days 13 16 .30
CDAD relapsea 5 (31) 5 (36) 1.0
Acute renal failure
(creatinine level, x2.0 mg/dL) 0 (0) 7 (33) .01
Acute liver dysfunction
(total bilirubin level, x4.0 mg/dL) 1 (6) 5 (24) .20
BSI rate, cases per 1,000 patient-daysb 5.7 11.5 .06
BSI due to enteric organismbc 4 (31) 14 (82) .004
note. Data are no. (%) of patients, unless indicated otherwise. BSI, bloodstream infection; Mtz,
metronidazole; Vm, vancomycin.
a Among the patients alive at discharge (mild to moderate CDAD, 16 patients; severe CDAD, 14
patients).
b Includes only BSI after onset of CDAD (relative rate, 2.0 [95% confidence interval, 1.0-4.1]).
c Of the total number of BSIs (patients with mild to moderate CDAD, 13 cases of BSI; patients with
severe CDAD, 17 cases of BSI). BSI in patients with mild or moderate CDAD was caused by coagulase-
negative Staphylococcus (6 cases), Klebsiella pneumoniae (2), Klebsiella oxytoca, Escherichia coli, meth-
icillin-resistant Staphylococcus aureus, viridans group Streptococcus, and Stomatococcus species. BSIs in
patients with severe CDAD were caused by vancomycin-resistant enterococci (5 cases), coagulase-
negative Staphylococcus (3), Enterococcus faecalis (2), Candida albicans (2), Candida tropicalis (2), K.
pneumoniae, K. oxytoca, and Pseudomonas aeruginosa.
days since transplantation, graft-versus-host disease, neutro-
penia at the time of CDAD diagnosis, or number of days
hospitalized before CDAD. The CDAD symptoms seen most
frequently within 48 hours of diagnosis were diarrhea (in 31
patients [84%]), fever (in 13 [35%]), and abdominal pain
(in 9 [24%]).
Patients with severe CDAD had significantly more adverse
outcomes than did patients with mild or moderate CDAD
(Table). Patients with severe CDAD were more likely to be
treated with metronidazole and vancomycin or vancomy-
cin alone than were patients with mild or moderate CDAD
( ). Compared with patients with mild or moderatePp .05
CDAD, a larger number of patients with severe CDAD re-
quired more than 2 days to respond to therapy ( ),Pp .05
and more of these patients had acute renal failure after the
onset of CDAD ( ). Patients with severe CDAD hadPp .01
a higher rate of bloodstream infection (BSI) after CDAD (11.5
vs 5.7 cases per 1,000 patient-days; relative rate, 2.0 [95%
confidence interval, 1.0-4.1]). Significantly more cases of BSI
due to enteric organisms occurred among patients with severe
CDAD than among patients with mild or moderate CDAD
( ). The median survival time after CDAD was 266Pp .004
days for patients with mild or moderate CDAD and 55 days
for patients with severe CDAD (log-rank ) (Figure).Pp .003
discussion
This study is the first, to our knowledge, to provide a method
for grading CDAD severity in allogeneic stem cell transplant
recipients. Previously published CDAD severity grading sys-
tems were developed on the basis of outcomes and charac-
teristics seen in patients with CDAD throughout their clinical
course.14,15 The grading system presented herein was devel-
oped on the basis of clinical presentation (symptoms present
within 48 hours before or after CDAD diagnosis). Application
of this system identified patients at increased risk for adverse
events associated with CDAD. Patients with severe CDAD
were more likely to be treated with vancomycin or metro-
nidazole plus vancomycin than were patients with mild or
moderate CDAD. Metronidazole is first-line therapy for
CDAD at our institution, and vancomycin is used for severe
or refractory CDAD. The increased use of vancomycin among
patients with severe CDAD suggests that the treating physi-
cians perceived these patients’ symptoms to be more severe
than those of other patients or refractory to metronidazole
therapy. Significantly more patients with severe CDAD re-
quired more than 2 days to respond to antimicrobial therapy
and experienced acute renal failure after CDAD onset than
did patients with mild or moderate CDAD.
Significantly more cases of BSI caused by enteric organisms
210 infection control and hospital epidemiology february 2007, vol. 28, no. 2
figure. Survival rates 180 days after diagnosis among patients
with mild to moderate Clostridium difficile–associated disease
(CDAD) and patients with severe CDAD.
occurred after onset of CDAD in patients with severe CDAD
than in patients with mild or moderate CDAD. Sepsis and
bacteremia associated with CDAD have been reported pre-
viously16-20; however, the association between CDAD and BSI
caused by gastrointestinal organisms has not been as well
studied. C. difficile toxins A and B directly damage colonic
mucosa and could thereby lead to BSI.
Most striking is the significant decrease in survival time
for those patients who had severe CDAD. This finding has
several possible explanations. It is possible that the patients
with severe CDAD were initially more ill than patients with
mild or moderate CDAD. Although no statistically significant
differences were found, prior to CDAD diagnosis, between
those patients who developed mild or moderate CDAD and
those who developed severe CDAD, assessing severity of ill-
ness by retrospective medical record review can be difficult.
Alternatively, the increased risk of death may have been the
result of the severity of CDAD.
This study has a few limitations. The sample size was small;
however, 37 patients with CDAD is a larger sample group
than any previously published cohort of CDAD cases in al-
logeneic transplant recipients. Allogeneic stem cell transplant
recipients are highly immunocompromised, and diarrhea is
common in these patients.3,9,10 The symptoms used to evaluate
CDAD severity may have been the result of other causes.
Potential bias attributable to the ubiquity of CDAD symptoms
should have been minimized by limiting the analysis to symp-
toms experienced within 48 hours before or after CDAD di-
agnosis. By excluding severe symptoms experienced more
than 48 hours before or after diagnosis but potentially truly
due to CDAD, any remaining bias should be toward the null
hypothesis (ie, more cases mistakenly categorized as mild or
moderate).
Despite the small sample size and the complex nature of
the study population, this CDAD severity grading system
identified patients at high risk for adverse outcomes after
CDAD based on presenting symptoms. In addition, an im-
portant benefit of this system is the ease with which it can
be used. Because both the incidence of CDAD and the size
of the immunocompromised population are increasing, a
CDAD severity grading system such as the one presented
herein may become critical to early identification of patients
at high risk for adverse events associated with CDAD. Pro-
spective validation of this system is needed.
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